The trial attained equally its Main endpoints, with semaglutide two.4 mg demonstrating statistically important and top-quality enhancements in liver fibrosis without worsening of steatohepatitis, along with resolution of steatohepatitis without worsening of liver fibrosis in people with MASH compared to placebo.1If you have any opinions or would wa